ANI Pharmaceuticals (ANIP)

[jadite]

Hi Jeff,

From the conference call 8/4:

"both nilutamide and the anti-infective product that I mentioned we feel could generate approximately $20 million in combined EBITDA annual basis. So I think you have let’s say the ammunition to take a look at our sequential run rates for the quarter."

We know Art Przybyl does not exaggerate.
Your hot NYC summer must be starting to cool. Perfect.